A new infliximab or intravenously injected drug called Lei Ting, produced by Taizhou Mabtech Pharmaceutical Co – based in the Taizhou Medical High-tech Zone in Taizhou city, East China's Jiangsu province – recently got the green light to be sold on the Peruvian market.
The expansion into the Peruvian market is seen as an important milestone for enterprises that have settled in the zone to widen their overseas markets.
Approved for the Chinese market in July 2021, Lei Ting is used for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, adult ulcerative colitis, Crohn's disease in adults and children over 6 years old, as well as fistulous Crohn's disease.
Set up in the zone in 2015, Taizhou Mabtech Pharmaceutical Co is a wholly owned subsidiary of Mabpharm Limited. Mabpharm Limited focuses on the research, development and production of new drugs and biosimilars for cancers and autoimmune diseases.
Taizhou Mabtech Pharmaceutical Co possesses multiple core technologies and a leading large-scale antibody preparations system. An 80,000-square meter production workshop with a total reactor capacity of over 40,000 liters has been built in the Taizhou zone. The group boasts a senior research and development team, with core members having over 20 years each of experience in antibody drug development.
An exterior view of Taizhou Mabtech Pharmaceutical Co Ltd. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]